Bayer Global Investments (OTCPK:BAYRY) has cut its stake in CRISPR Therapeutics (NASDAQ:CRSP) to 7.2%, according to a filing.
It got there (from a previous stake of about 9.5%) by selling about 1.4M shares on a range of dates from Dec. 18 to Jan. 8, according to the filing.
As of its original filing date, Bayer beneficially owned 12.8% of CRISPR.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.